RT + 5-FU + Mito-C vs. RT + 5-FU + CDDP

Phase II Rebeccamycin

Phase II study of oral Xeloda in combination with intravenous Irinotecan

Phase II multicenter study of Erbitux™ (Cetuximab) in patients with metastatic colorectal carcinoma

Phase II study safety and immunogenicity of ALVAC-CEA/B7.1 vaccine

A feasibility study of Oxaliplatin in combination with an infusional or weekly bolus 5-FU/LV or Capecitabine as first line treatment of patients with advanced colorectal cancer

Randomized Phase II equivalence trial of Irinotecan vs. Oxaliplatin in combination with an infusional or weekly bolus 5-FU/LV or Capecitabine as first line treatment of patients with advanced colorectal cancer

Phase IIB evaluation of Cyclooxygenase-2 activity in surgically resected primary colorectal adenomas and carcinomas after 7 days pretreatment with Celecoxib

A Phase II study of Irinotecan and Taxotere with concurrent radiotherapy as a preoperative treatment in resectable esophageal cancer

A Phase I/II open label study of T138057-sodium in patients with advanced, surgically unresectable hepatocellular carcinoma

Phase II Rebeccamycin

Phase III PN-401 with High Dose 5FU vs. Gemcitabine

Randomized, placebo-controlled, double blind Phase II study of Gemcitabine + Ly293111 compared to Gemcitabine + placebo in patients with locally advanced or metastatic pancreatic cancer

Phase I DX-8951f in patients with liver dysfunction

Phase I DX-891f in patients with renal dysfunction